Neimeth International Pharmaceuticals Plc

NGSE:NEIMETH Stock Report

Market Cap: ₦7.5b

Neimeth International Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Neimeth International Pharmaceuticals's earnings have been declining at an average annual rate of -78.1%, while the Pharmaceuticals industry saw earnings growing at 6.8% annually. Revenues have been growing at an average rate of 0.5% per year.

Key information

-78.1%

Earnings growth rate

-67.5%

EPS growth rate

Pharmaceuticals Industry Growth21.6%
Revenue growth rate0.5%
Return on equity-156.4%
Net Margin-116.8%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Neimeth International Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NGSE:NEIMETH Revenue, expenses and earnings (NGN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 232,210-2,5811,4100
30 Sep 231,919-1,0971,3890
30 Jun 232,242-9531,4100
31 Mar 232,595-6151,1520
31 Dec 223,457191,1700
30 Sep 222,703-1101,1250
30 Jun 222,882521,1740
31 Mar 222,750331,1780
31 Dec 212,8441401,1330
30 Sep 213,0472711,0740
30 Jun 212,824601,0050
31 Mar 212,9561841,0010
31 Dec 202,627-499840
30 Sep 202,8392129390
30 Jun 202,9674278930
31 Mar 202,5602717800
31 Dec 192,7514427710
30 Sep 192,3712207450
30 Jun 192,3451188030
31 Mar 192,3681248990
31 Dec 182,102-59030
30 Sep 182,2691488970
30 Jun 181,952-918560
31 Mar 181,810-1878720
31 Dec 171,791-1508710
30 Sep 171,534-4119580
30 Jun 171,718-3119700
31 Mar 171,816-2319580
31 Dec 161,743-2359130
30 Sep 162,002658390
30 Jun 161,664-1628970
31 Mar 161,808-549280
31 Dec 151,588-2169230
30 Sep 151,461-3368890
30 Jun 151,313-2978760
31 Mar 151,261-3978560
31 Dec 141,429-3729070
30 Sep 141,628-2298910
30 Jun 142,0001161,4620
31 Mar 142,105869040
31 Dec 132,1501788820
30 Sep 132,0171318730
30 Jun 131,829-3900
31 Mar 131,443-6600

Quality Earnings: NEIMETH is currently unprofitable.

Growing Profit Margin: NEIMETH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NEIMETH is unprofitable, and losses have increased over the past 5 years at a rate of 78.1% per year.

Accelerating Growth: Unable to compare NEIMETH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NEIMETH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.2%).


Return on Equity

High ROE: NEIMETH has a negative Return on Equity (-156.36%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.